Assessment of the durability of the immune response against GBM in mice treated with VEGF-C revealed that mice rejecting an intracranial tumor rechallenge with GL261 in the flank exhibit no detectable tumors and demonstrate long-term systemic memory responses [30]. The gene discussed is VEGFC; the disease is glioblastoma.